Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitReceivables - NetReceivables - OtherShares OutstandingShares OutstandingShort-Term Debt repayments
Ratios

Medicure (MCUJF) Cost of Revenue (2016 - 2025)

Medicure has reported Cost of Revenue over the past 17 years, most recently at $4.2 million for Q4 2025.

  • For Q4 2025, Cost of Revenue rose 138.64% year-over-year to $4.2 million; the TTM value through Dec 2025 reached $12.3 million, up 90.87%, while the annual FY2025 figure was $12.3 million, 94.34% up from the prior year.
  • Cost of Revenue for Q4 2025 was $4.2 million at Medicure, up from $3.9 million in the prior quarter.
  • Over five years, Cost of Revenue peaked at $7.9 million in Q4 2021 and troughed at $1.0 million in Q3 2023.
  • A 5-year average of $2.1 million and a median of $1.6 million in 2021 define the central range for Cost of Revenue.
  • Biggest five-year swings in Cost of Revenue: surged 393.48% in 2021 and later tumbled 81.86% in 2022.
  • Year by year, Cost of Revenue stood at $7.9 million in 2021, then tumbled by 81.86% to $1.4 million in 2022, then skyrocketed by 37.94% to $2.0 million in 2023, then dropped by 11.62% to $1.8 million in 2024, then skyrocketed by 138.64% to $4.2 million in 2025.
  • Business Quant data shows Cost of Revenue for MCUJF at $4.2 million in Q4 2025, $3.9 million in Q3 2025, and $2.3 million in Q2 2025.